Cargando…
mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy
mRNA therapy is a novel anticancer strategy based on in vitro transcription (IVT), which has potential for the treatment of malignant tumors. The outbreak of the COVID-19 pandemic in the early 21st century has promoted the application of mRNA technologies in SARS-CoV-2 vaccines, and there has been a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201022/ https://www.ncbi.nlm.nih.gov/pubmed/35720301 http://dx.doi.org/10.3389/fimmu.2022.887125 |
_version_ | 1784728195218538496 |
---|---|
author | Deng, Zhuoya Tian, Yuying Song, Jianxun An, Guangwen Yang, Penghui |
author_facet | Deng, Zhuoya Tian, Yuying Song, Jianxun An, Guangwen Yang, Penghui |
author_sort | Deng, Zhuoya |
collection | PubMed |
description | mRNA therapy is a novel anticancer strategy based on in vitro transcription (IVT), which has potential for the treatment of malignant tumors. The outbreak of the COVID-19 pandemic in the early 21st century has promoted the application of mRNA technologies in SARS-CoV-2 vaccines, and there has been a great deal of interest in the research and development of mRNA cancer vaccines. There has been progress in a number of key technologies, including mRNA production strategies, delivery systems, antitumor immune strategies, etc. These technologies have accelerated the progress and clinical applications of mRNA therapy, overcoming problems encountered in the past, such as instability, inefficient delivery, and weak immunogenicity of mRNA vaccines. This review provides a detailed overview of the production, delivery systems, immunological mechanisms, and antitumor immune response strategies for mRNA cancer vaccines. We list some mRNA cancer vaccines that are candidates for cancer treatment and discuss clinical trials in the field of tumor immunotherapy. In addition, we discuss the immunological mechanism of action by which mRNA vaccines destroy tumors as well as challenges and prospects for the future. |
format | Online Article Text |
id | pubmed-9201022 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92010222022-06-17 mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy Deng, Zhuoya Tian, Yuying Song, Jianxun An, Guangwen Yang, Penghui Front Immunol Immunology mRNA therapy is a novel anticancer strategy based on in vitro transcription (IVT), which has potential for the treatment of malignant tumors. The outbreak of the COVID-19 pandemic in the early 21st century has promoted the application of mRNA technologies in SARS-CoV-2 vaccines, and there has been a great deal of interest in the research and development of mRNA cancer vaccines. There has been progress in a number of key technologies, including mRNA production strategies, delivery systems, antitumor immune strategies, etc. These technologies have accelerated the progress and clinical applications of mRNA therapy, overcoming problems encountered in the past, such as instability, inefficient delivery, and weak immunogenicity of mRNA vaccines. This review provides a detailed overview of the production, delivery systems, immunological mechanisms, and antitumor immune response strategies for mRNA cancer vaccines. We list some mRNA cancer vaccines that are candidates for cancer treatment and discuss clinical trials in the field of tumor immunotherapy. In addition, we discuss the immunological mechanism of action by which mRNA vaccines destroy tumors as well as challenges and prospects for the future. Frontiers Media S.A. 2022-06-02 /pmc/articles/PMC9201022/ /pubmed/35720301 http://dx.doi.org/10.3389/fimmu.2022.887125 Text en Copyright © 2022 Deng, Tian, Song, An and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Deng, Zhuoya Tian, Yuying Song, Jianxun An, Guangwen Yang, Penghui mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy |
title | mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy |
title_full | mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy |
title_fullStr | mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy |
title_full_unstemmed | mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy |
title_short | mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy |
title_sort | mrna vaccines: the dawn of a new era of cancer immunotherapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201022/ https://www.ncbi.nlm.nih.gov/pubmed/35720301 http://dx.doi.org/10.3389/fimmu.2022.887125 |
work_keys_str_mv | AT dengzhuoya mrnavaccinesthedawnofaneweraofcancerimmunotherapy AT tianyuying mrnavaccinesthedawnofaneweraofcancerimmunotherapy AT songjianxun mrnavaccinesthedawnofaneweraofcancerimmunotherapy AT anguangwen mrnavaccinesthedawnofaneweraofcancerimmunotherapy AT yangpenghui mrnavaccinesthedawnofaneweraofcancerimmunotherapy |